Xilio Therapeutics, Inc.
XLO- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001840233
No open-market purchases or sales by Xilio Therapeutics, Inc. insiders were filed in the last 90 days; 27 institutions reported holding it in 13F filings for Q2 2026, worth $32.6M in total; no superinvestor holds it.
13F holders, Q3 2022
Institutional positions in Xilio Therapeutics, Inc. as of Sep 30, 2022. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 29
- −4 vs. Q2 2022
- Shares held
- 16.6M
- −1.27M (−7.1%) vs. Q2 2022
- Total value
- $48.3M
- −$3.89M (−7.4%) vs. Q2 2022
- New holders
- 3
- 3 more added
- Sold out
- 7
- 9 more reduced
Compare with Q2 2022: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting XLO on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 27 | $32.6M |
| Q1 2026 | 24 | $22.0M |
| Q4 2025 | 37 | $25.4M |
| Q3 2025 | 36 | $18.6M |
| Q2 2025 | 35 | $16.2M |
| Q1 2025 | 35 | $16.3M |
| Q4 2024 | 35 | $24.7M |
| Q3 2024 | 33 | $12.6M |
| Q2 2024 | 32 | $13.7M |
| Q1 2024 | 31 | $13.5M |
| Q4 2023 | 34 | $9.03M |
| Q3 2023 | 31 | $33.5M |
| Q2 2023 | 32 | $41.9M |
| Q1 2023 | 32 | $51.0M |
| Q4 2022 | 28 | $42.8M |
| Q3 2022 | 29 | $48.3M |
| Q2 2022 | 33 | $52.2M |
| Q1 2022 | 41 | $132.7M |
| Q4 2021 | 42 | $303.1M |
| Q3 2021 | 0 | $0 |
| Q2 2021 | 0 | $0 |
| Q1 2021 | 0 | $0 |
Institutions, Q3 2022
Shares, value and share of portfolio for each institution holding Xilio Therapeutics, Inc.; share changes are against Q2 2022.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Wells Fargo & Company | 75 | $0 | 0.00% | +24+47.1% | Added |
| UBS Group AG | 201 | $1.00K | 0.00% | −2,613−92.9% | Reduced |
| Tower Research Capital LLC (TRC) | 2,069 | $6.00K | 0.00% | −4,086−66.4% | Reduced |
| JPMorgan Chase & Co | 2,704 | $8.00K | 0.00% | −31−1.1% | Reduced |
| Morgan Stanley | 6,840 | $20.0K | 0.00% | −200−2.8% | Reduced |
| RBF Capital, LLC | 10,072 | $29.0K | 0.00% | 00.0% | Unchanged |
| Nwam LLC | 10,000 | $29.0K | 0.00% | +10,000 | New |
| Ergoteles LLC | 12,941 | $38.0K | 0.00% | −4,607−26.3% | Reduced |
| Northern Trust Corp | 12,900 | $38.0K | 0.00% | 00.0% | Unchanged |
| State Street Corp | 15,690 | $46.0K | 0.00% | 00.0% | Unchanged |
| Cannell Capital LLC | 17,025 | $50.0K | 0.01% | +12,480+274.6% | Added |
| Millennium Management LLC | 27,631 | $80.0K | 0.00% | −22,325−44.7% | Reduced |
| Renaissance Technologies LLC | 28,500 | $83.0K | 0.00% | −46,800−62.2% | Reduced |
| BlackRock Inc. | 46,358 | $135.0K | 0.00% | −1,305−2.7% | Reduced |
| Bridgeway Capital Management, LLC | 76,081 | $221.0K | 0.01% | +76,081 | New |
| Geode Capital Management, LLC | 83,589 | $243.0K | 0.00% | 00.0% | Unchanged |
| Laurion Capital Management LP | 142,900 | $416.0K | 0.01% | 00.0% | Unchanged |
| FIL Ltd | 218,705 | $636.0K | 0.00% | 00.0% | Unchanged |
| Harvard Management Co Inc | 416,059 | $1.21M | 0.15% | 00.0% | Unchanged |
| Artal Group S.A. | 450,000 | $1.31M | 0.07% | 00.0% | Unchanged |
| Soleus Capital Management, L.P. | 453,660 | $1.32M | 0.18% | 00.0% | Unchanged |
| AJU IB Investment Co., Ltd. | 667,742 | $1.94M | 3.33% | 00.0% | Unchanged |
| Vanguard Group Inc | 891,533 | $2.60M | 0.00% | +472,368+112.7% | Added |
| Rock Springs Capital Management LP | 1,362,878 | $3.97M | 0.10% | 00.0% | Unchanged |
| RiverVest Venture Management LLC | 1,441,444 | $4.20M | 4.87% | 00.0% | Unchanged |
| FMR LLC | 2,219,762 | $6.46M | 0.00% | −301,571−12.0% | Reduced |
| Octagon Capital Advisors LP | 2,425,000 | $7.06M | 1.22% | +2,425,000 | New |
| Atlas Venture Life Science Advisors, LLC | 2,759,344 | $8.03M | 0.89% | 00.0% | Unchanged |
| Bain Capital Life Sciences Investors, LLC | 2,805,413 | $8.16M | 0.97% | 00.0% | Unchanged |
| Deerfield Management Company, L.P. (Series C) | 0 | $0 | 0.00% | −2,078,692−100.0% | Sold out |
| Ra Capital Management, L.P. | 0 | $0 | 0.00% | −1,649,711−100.0% | Sold out |
| Norges Bank | 0 | $0 | 0.00% | −121,887−100.0% | Sold out |
| Bailard, Inc. | 0 | $0 | 0.00% | −36,632−100.0% | Sold out |
| New York State Common Retirement Fund | 0 | $0 | 0.00% | −64−100.0% | Sold out |
| Credit Suisse AG | 0 | $0 | 0.00% | −4−100.0% | Sold out |
| Citigroup Inc | 0 | $0 | 0.00% | −67−100.0% | Sold out |